1.13
Schlusskurs vom Vortag:
$1.16
Offen:
$1.21
24-Stunden-Volumen:
251.76K
Relative Volume:
0.26
Marktkapitalisierung:
$4.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.78M
KGV:
-0.0265
EPS:
-42.6996
Netto-Cashflow:
$-4.67M
1W Leistung:
+16.26%
1M Leistung:
+27.47%
6M Leistung:
-22.07%
1J Leistung:
-32.34%
Clearmind Medicine Inc Stock (CMND) Company Profile
Firmenname
Clearmind Medicine Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CMND mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CMND
Clearmind Medicine Inc
|
1.13 | 5.23M | 0 | -6.78M | -4.67M | -42.70 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
What analysts say about Clearmind Medicine Inc. stockHigh-yield investments - jammulinksnews.com
Is Clearmind Medicine Inc. a good long term investmentGame-changing returns - jammulinksnews.com
What drives Clearmind Medicine Inc. stock priceOutstanding stock performance - jammulinksnews.com
Clearmind Medicine Inc. Stock Analysis and ForecastFree Capital Growth Strategies - jammulinksnews.com
Clearmind Medicine Surges 18.99%: What's Fueling This Volatile Biotech Rally? - AInvest
How Clearmind Medicine Inc. stock reacts to Fed policy changesFree Access to Community with 300% Return - beatles.ru
What makes Clearmind Medicine Inc. stock price move sharplySmart Money Trade Setups - beatles.ru
Clearmind Expands its Clinical Trial for Alcohol Use, New Site Activated and Additional Participant Enrolled - MarketScreener
How Clearmind Medicine Inc. stock performs during market volatilityFree High-Accuracy Stock Picks - Newser
Why Clearmind Medicine Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser
Clearmind Expands Its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled - MarketScreener
Clearmind expands phase I/IIa trial for alcohol use disorder treatment By Investing.com - Investing.com South Africa
Clearmind expands phase I/IIa trial for alcohol use disorder treatment - Investing.com India
Clearmind Medicine Inc. Expands Phase I/IIa Clinical Trial for CMND-100 to Johns Hopkins University to Address Alcohol Use Disorder - Nasdaq
Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled - The Manila Times
Clearmind Medicine (NASDAQ:CMND) Stock Price Up 4.5% – Here’s Why - Defense World
Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck - Yahoo Finance
Clearmind Medicine Soars 32.89% on Clinical Trial Approval - AInvest
CMND’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Clearmind Gains IRB Approval At TASMC For Alcohol Use Disorder Drug Trial - Nasdaq
Clearmind’s Stock Gains Momentum with New Trial Expansions - timothysykes.com
Clearmind Medicine’s Rise: What’s Steering the Surge? - timothysykes.com
Clearmind receives IRB approval for alcohol disorder treatment trial - Investing.com
Clearmind receives IRB approval for alcohol disorder treatment trial By Investing.com - Investing.com South Africa
Clearmind Medicine Inc. Receives IRB Approval for Phase 1/2a Clinical Trial of CMND-100 for Alcohol Use Disorder - Nasdaq
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder - The Manila Times
Clearmind doses first participant in alcohol disorder treatment trial - Investing.com
Clearmind doses first participant in alcohol disorder treatment trial By Investing.com - Investing.com Canada
Clearmind Medicine's Global AUD Trial Expansion: Seizing the $775M Market's Psychedelic Opportunity - AInvest
Clearmind adds Hadassah Medical Center to alcohol disorder drug trial By Investing.com - Investing.com South Africa
Clearmind Adds New Site to Trial for Experimental Alcohol Use Disorder Drug - MarketScreener
Clearmind enrolls first patient in CMND-100 alcohol disorder trial - Investing.com India
Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment - Yahoo Finance
Clearmind Medicine Inc. Engages Consulting Firm to Advance Psychedelic-Based Treatments and Regulatory Advocacy - Nasdaq
Clearmind adds Tel Aviv medical center to alcohol disorder drug trial - Investing.com India
Clearmind Medicine Inc. Expands Phase I/IIa Clinical Trial for CMND-100 with Tel Aviv Sourasky Medical Center Collaboration - Nasdaq
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update - Defense World
Finanzdaten der Clearmind Medicine Inc-Aktie (CMND)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):